| Document |
Document Title |
|
WO/2023/229295A1 |
The present invention relates to a phenylpropene derivative, and a pharmaceutical composition for the prevention or treatment of cancer, comprising the phenylpropene derivative as an active ingredient. The phenylpropene derivative disclo...
|
|
WO/2023/229293A1 |
The present invention relates a bicycle derivative and a pharmaceutical composition comprising same as an active ingredient for the prevention or treatment of cancer. Found to have ACC inhibitory activity involved in the inhibitory mecha...
|
|
WO/2023/230428A1 |
Provided herein are mineral:amino acid complexes wherein the mineral comprises a macronutrient or micronutrient of agrochemical interest. The amino acid may comprise, for example, glycine or lysine. The mineral may comprise, for example,...
|
|
WO/2023/226263A1 |
The present invention relates to the technical field of organic synthesis, in particular to an anilinoacetate and a synthesis method therefor. The synthesis method for an anilinoacetate comprises: S1, adding an anilinoacetate solution an...
|
|
WO/2023/196527A3 |
Novel ionizable lipids, compositions, and methods of using the novel ionizable lipids of formula (I) and compositions are disclosed. Lipid nanoparticle compositions include a novel ionizable lipid as well as additional lipids such as pho...
|
|
WO/2023/230041A2 |
The present disclosure describes an L-S2-amino-4-halobutyric acid derivative-L-tartrate salt. The present disclosure also describes a method of preparing L-S-amino-4-halobutyric acid derivative-L-tartrate salt, comprising the following s...
|
|
WO/2023/222081A1 |
Provided are a long-chain alkyl ester amine lipid compound represented by formula I, a preparation method therefor, and a use thereof in nucleic acid delivery. The long-chain alkyl ester amine lipid compound, as a lipid molecule, has exc...
|
|
WO/2023/225144A1 |
The invention provides piperidinyl-methyl-purine amine salts, crystalline forms, pharmaceutical compositions, their use in inhibiting NSD2, and their use in the treatment of a disease or condition, such as cancer.
|
|
WO/2023/224418A1 |
The present invention relates to a method for producing, from fatty alcohols, various monomers that are used in the production of synthetic resins.
|
|
WO/2023/222938A1 |
The present invention relates to coordination compounds, specifically to lanthanide coordination compounds that are proven to be useful as anti-inflammatory agents. The present invention further relates to novel gadolinium coordination c...
|
|
WO/2023/225050A1 |
Disclosed herein are high dielectric constant zwitterionic compounds of Formula (I) and methods of making the same. These materials are liquid near room temperature, with unprecedentedly high dielectric constants, making them both novel ...
|
|
WO/2023/217119A1 |
Disclosed herein is a diclofenac prodrug represented by formula (I), wherein each of the substituents is given the definition as set forth in the Specification and Claims. Also disclosed is a method for alleviating arthritis, which inclu...
|
|
WO/2023/219152A1 |
One aspect of the present invention relates to a method for producing a salt of an amino acid, a salt of a peptide compound, or a solvate of either one of the salts, the method comprising the following steps (A) and (B). Step (A): a st...
|
|
WO/2023/219156A1 |
One aspect of the present invention pertains to a method for producing an amino acid, the method comprising a step for conducting a reaction of (i) or (ii), in the presence of a compound D represented by formula (1), a reducing agent, an...
|
|
WO/2023/212795A1 |
A use of a compound of the class of glycine transporter-1 antagonist compounds as a vascular dementia prophylactic/treatment agent is provided. Furthermore, a use of a compound of the class of glycine transporter-1 antagonist compounds a...
|
|
WO/2023/215742A2 |
The invention provides a method for preparing an amine product in a single reaction mixture, comprising incubating a biomass-derived or plastics-derived aryl or heterocyclic carboxylic acid, a carboxylic acid reductase (CAR), and a co-tr...
|
|
WO/2023/211956A1 |
Esterquat fabric softening compositions are disclosed that comprise an esterquat fabric softening active derived from biorenewable sources and having a Biorenewable Carbon Index (BCI) of 100. The esterquat fabric softening active is the ...
|
|
WO/2023/207101A1 |
Provided herein is a class of ionizable lipid compounds represented by formula (IV), or pharmaceutically acceptable salts, isotopic variants, tautomers or stereoisomers thereof. Also provided is a nanoparticle pharmaceutical composition ...
|
|
WO/2023/203897A1 |
The present invention provides a diamine represented by formula (1); a method for producing the same; and a polyamic acid and polyimide produced from this diamine.
|
|
WO/2023/202554A1 |
Disclosed are a chiral aryl propionic acid derivative and a pharmaceutical composition thereof, and a use. The chiral aryl propionic acid derivative is as shown in formula (I), and the definition of each group is given in the description...
|
|
WO/2023/200346A1 |
A new 1D silver coordination polymer built of the 1,3,5-triaza-7-phosphaadamantane aminophosphine, diclofenac and silver(I) ions is disclosed, the method of preparation and medical use thereof, especially for the treatment of pancreatic ...
|
|
WO/2023/201301A2 |
The present disclosure relates, in part, to biodegradable lipid nanoparticles (LNPs) comprising biodegradable lipidoid compounds and compositions thereof. In certain embodiments, the LNPs selectively target a cell of interest (e.g., an i...
|
|
WO/2023/199754A1 |
The present invention provides a composite of a hydrotalcite compound and an amino acid in which the aspect ratio is high and it is possible to control colorability. The composite includes a hydrotalcite compound and an amino acid. The...
|
|
WO/2023/198200A1 |
The present disclosure provides a conjugate. The conjugate comprises one or more delivery groups and one or more functional groups. Each of the delivery groups is independently connected to the functional group by means of a covalent bon...
|
|
WO/2023/196527A2 |
Novel ionizable lipids, compositions, and methods of using the novel ionizable lipids and compositions are disclosed. Lipid nanoparticle compositions include a novel ionizable lipid as well as additional lipids such as phospholipids, str...
|
|
WO/2023/187044A1 |
A process for the production of a surfactant of formula (I) is provided, as well as a surfactant composition. Moreover, specific surfactants and compositions thereof are provided, as well as their use in a wide variety of applications su...
|
|
WO/2023/190878A1 |
Provided is a tetrahydronaphthalene derivative that can be used as an LAT1-selective inhibitor and an LAT1-selective substrate. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable sal...
|
|
WO/2023/187602A1 |
The present invention relates to the process for obtaining disodium tyrosine, preferably dihydrate, in a crystalline form, by spray drying technology.
|
|
WO/2023/192099A1 |
A method of making a biodegradable piezoelectric composite material is provided. Such a method may include mixing a solution comprising biodegradable polymer, glycine crystal, and at least one solvent. The method further comprises electr...
|
|
WO/2023/190130A1 |
Provided is an aqueous fibroin solution having high storage stability and excellent foam formation ability, and a production method thereof. This aqueous fibroin solution contains fibroin and a compound represented by general formula (1)...
|
|
WO/2023/186167A1 |
Disclosed is a cationic lipid having the following general formula (I), wherein A, B, C, and D are each as defined in the description. Also disclosed are a liposome and a lipid nanoparticle containing the cationic lipid, and use of the c...
|
|
WO/2023/187049A1 |
The present invention relates to a process for separating at least one ε-caprolactam oligomeric compound CPO from a stream SR comprising said at least one CPO and ε-caprolactam monomeric compound CPM.
|
|
WO/2023/187622A1 |
Compositions, solutions, products, devices, and methods related to EDTA, and uses thereof in treating pulmonary diseases and disorders such as cystic fibrosis are disclosed. Also disclosed are an inhalation device and an EDTA composition...
|
|
WO/2023/186171A1 |
Disclosed is a cationic lipid having the following general formula (I), wherein A, B, C, and D are each as defined in the description. Also disclosed are a liposome and a lipid nanoparticle comprising the cationic lipid, and use of the c...
|
|
WO/2023/179463A1 |
The present invention relates to a cationic lipid compound, a preparation method therefor and the use thereof, and an mRNA delivery system, which relate to the technical field of medical biology. The problem of there being an urgent need...
|
|
WO/2023/179462A1 |
Disclosed in the present invention are a cationic lipid compound, a preparation method therefor and the use thereof, and an mRNA delivery system, which solve the problem of there being an urgent need to develop cationic lipids with high ...
|
|
WO/2023/181053A1 |
The present invention relates to an improved process for purification of Robenacoxib. More particularly, the present invention relates to a process for obtaining crystalline Robenacoxib in high yield with high purity. Furthermore, the pr...
|
|
WO/2023/181030A1 |
The present invention relates to novel a pesticidally and/or herbicidally active compounds, agrochemical composition thereof, methods of preparation thereof, and uses thereof for controlling the growth of undesirable plants (e.g., weeds)...
|
|
WO/2023/179499A1 |
The present invention relates to the field of gene drug delivery, and particularly to a lipid compound having a glycerol skeleton, a lipid carrier based on the lipid compound, a nucleic acid lipid nanoparticle composition, and a pharmace...
|
|
WO/2023/180282A1 |
The present invention concerns a co-precipitate of methionylmethonine with at least one further organic compound, preferably with aminolevulinic acid, PQQ or thiamine, methods for preparing such co-precipitates and the use of such co-pre...
|
|
WO/2023/179497A1 |
The present invention belongs to the field of gene drug delivery, and particularly relates to a lipid compound, a lipid carrier based on the lipid compound, a nucleic acid lipid nanoparticle composition and a pharmaceutical formulation. ...
|
|
WO/2023/176918A1 |
The purpose of the present invention is to provide a metal-organic framework that exhibits an excellent adsorption performance for adsorption target substances. The present invention is a metal-organic framework that has a decomposition ...
|
|
WO/2023/178065A2 |
Provided herein are lipid compounds, e.g., a compound of Formula (I). Also provided are lipid nanoparticles, each comprising a lipid compound of Formula (I).
|
|
WO/2023/176917A1 |
The purpose of the present invention is to provide an MOF that is capable of quickly adsorbing a target substance in accordance with a change in relative pressure and that exhibits an adsorption amount larger than or equal to a prescribe...
|
|
WO/2023/178266A2 |
The present disclosure relates to fluorinated phenylamino compounds, their pharmaceutical compositions, and methods for treating one or more tumors or cancers selected from the group consisting of plexiform neurofibromas (PN), plexiform ...
|
|
WO/2023/160702A1 |
The present disclosure relates to an amino lipid compound, a preparation method therefor, a composition thereof and the use thereof. Specifically, the present disclosure relates to an amino lipid compound represented by formula (I) or a ...
|
|
WO/2023/153504A1 |
A nucleic acid delivery material containing a perylene-diimide-ring-free polycyclic aromatic compound having one or more primary, secondary, or tertiary amino groups or nitrogen-cation-containing groups has exceptional efficiency in nucl...
|
|
WO/2023/143601A1 |
Provided in the present invention are a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. In the present invention, a specific cationic lipid is selected for preparing a lipid nanoparticle mRNA vaccine, which is foun...
|
|
WO/2023/142600A1 |
The present invention relates to an ionizable amino lipid represented by formula (I) or a pharmaceutically acceptable salt thereof. The amino lipid can be used to deliver nucleic acids and small molecule drugs and has two ester bonds, wh...
|
|
WO/2023/143591A1 |
The present invention provides a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. It is found that the lipid nanoparticle mRNA vaccine prepared in the present invention by selecting a specific cationic lipid has bet...
|
